Reuters logo
BRIEF-Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa
2016年8月31日 / 中午11点42分 / 1 年前

BRIEF-Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

Aug 31 (Reuters) - Amarin Corporation Plc

* Amarin randomizes final patient into reduce-it cardiovascular outcomes study of Vascepa

* Continues to expect onset of final primary cardiovascular event to occur in second half of 2017, publication of trial results likely in 2018 Source text for Eikon: Further company coverage:

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below